3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
448
Melanoma
287
Squamous Cell Carcinoma of Head and Neck
229
Parkinson Disease 4, Autosomal Dominant Lewy Body
188
Neoplasms
180
Breast Neoplasms
161
Triple Negative Breast Neoplasms
160
Neoplasm Metastasis
155
Lung Neoplasms
140
Colorectal Neoplasms
140
Carcinoma, Renal Cell
129
Head and Neck Neoplasms
120
Stomach Neoplasms
103
Ovarian Neoplasms
100
Carcinoma, Transitional Cell
91
Urinary Bladder Neoplasms
80
Pancreatic Neoplasms
80
Endometrial Neoplasms
72
Carcinoma, Hepatocellular
72
Uterine Cervical Neoplasms
63
Esophageal Neoplasms
57
Recurrence
52
Prostatic Neoplasms
48
Sarcoma
43
Carcinoma
42
Glioblastoma
39
Carcinoma, Squamous Cell
39
Small Cell Lung Carcinoma
38
Hodgkin Disease
36
Lymphoma
34
Interventions
enzalutamide
8
Abiraterone Acetate
5
rucaparib
2
Prednisone
2
tildrakizumab
1
sabizabulin
1
pembrolizumab
1
fluzoparib
1
apatinib
1
abiraterone
1
Pluvicto
1
N-(2-(2,3-difluoro-6-benzylthio)-6-(3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide
1
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Castration Resistant Prostate Cancer
×
pembrolizumab
×
Clear all
NCT03658447
2023-07-28
PRINCE
Peter MacCallum Cancer Centre, Australia
Phase 1/2
Completed
37 enrolled